Clinical Trial

Evaluation of the Efficacy of the Composite WM Formula in Promoting GLP-1 Secretion

Completed
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to evaluate the physiological effects of a WM Formula on glucagon-like peptide-1 (GLP-1) secretion and glycemic regulation in adults with elevated body fat percentage. The WM Formula is a multi-component dietary supplement composed of Bifidobacterium breve (Active), Rocket Apple Extract Powder (Active), Probio-kombu Black Tea Powder (Active), Soy Protein (Excipient), Gum Acacia (Excipient), and Erythritol (Excipient). Participants enrolled in the study will be required to undergo blood collection, height measurement, body composition analysis, and questionnaire completion. Each testing session will take approximately 5 hours, and participants will need to complete two trial visits in total. There will be a 7-day washout period between the two trial sessions (i.e., after completion of the first trial, the second trial will be scheduled at least 7 days later). On each trial day, blood samples and relevant assessments will be conducted at the following time points: before ingestion of the test product or placebo, and at 15, 30, 45, 60, 90, 120, and 240 minutes post-ingestion.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-30.
Status change: Not Yet Recruiting → Completed 2026-05-08
Trial Details
NCT Number NCT07097987
Lead Sponsor TCI Co., Ltd.
Conditions Obesity
Enrollment 20 participants
Start Date 2026-04-15
Primary Completion 2026-04-24 (estimated)
Study Completion 2026-04-24 (estimated)
Updated on ClinicalTrials.gov 2026-05-13